Ajovy (fremanezumab), a calcitonin gene-related peptide (CGRP) monoclonal antibody, works by inhibiting CGRP receptor activation, potentially reducing neurogenic inflammation and modulating pain signaling pathways in Visual Snow Syndrome. By targeting the CGRP pathway, it may help mitigate neurological symptoms and provide symptomatic relief for patients experiencing persistent visual disturbances and neurological complications associated with the syndrome.